Patent intelligence · US
US 9074212
RNAi inhibition of alpha-ENaC expression
RNAi inhibition of alpha-ENaC expression
Patent details — US 9074212
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 7, 2015
- Expiration
- Jul 2, 2035
- Applicant
- Arrowhead Research Corporation
- Claims
- 20
- CPC classes
- A61K, A61K31/713, A61K45/06, A61P
Quick answer
US 9074212 (RNAi inhibition of alpha-ENaC expression) is held by Arrowhead Research Corporation. Status: granted. Granted Jul 7, 2015. Expires Jul 2, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Arrowhead Research Corporation
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/713, A61K45/06, A61P, A61P11/00, A61P11/06
More from Arrowhead Research Corporation
Related pharmaceutical patents in our USPTO index.
-
US 12378558
RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use
granted -
US 12365897
RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use
granted -
US 12365899
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
granted -
US 12221610
RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use
granted -
US 12188017
Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin
granted -
US 12173086
Alpha-v beta-6 integrin ligands and uses thereof
granted -
US 12116573
Targeting ligands for therapeutic compounds
granted -
US 12110492
RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use
granted
Related coverage
Frequently asked questions
What is US patent 9074212?
US 9074212 (RNAi inhibition of alpha-ENaC expression) is held by Arrowhead Research Corporation. Status: granted. Granted Jul 7, 2015. Expires Jul 2, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9074212?
Arrowhead Research Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 126 pharmaceutical patents for this assignee.
When does US 9074212 expire?
Our index shows an expiration date of Jul 2, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.